Business ❯ Healthcare ❯ Pharmaceuticals
Drug Development Oncology Drug Safety Safety Regulations Regulatory Compliance AstraZeneca Obesity Treatments Regulatory Approval Product Compliance Product Development Product Candidates Phase 3 Trials Drug Efficacy B-cell Malignancies Multiple Myeloma Lawsuits AI in Drug Development Jasper Therapeutics Kidney Disease China Operations siRNA Treatments Investor Relations Investigational Drugs Choroidal Melanoma VX-993 Market Competition Neuro-ophthalmology Targeted Therapies Cemdisiran Data Security Safety Concerns Osteogenesis Imperfecta Regulatory Approvals Dementia Treatments Phase 1 Trial Drug Candidates COVID-19 Treatments Pulmonary Arterial Hypertension COPD Treatment Type 2 Diabetes MariTide NeuroThera Labs Hyalofast DESTINY-Breast05 Cancer Treatments Artificial Intelligence Duchenne Muscular Dystrophy BMS and J&J Blood Thinner Phase 3 Results Cardiovascular Therapies Therapeutics Biologics License Application Essential Tremor Amgen In Vivo CAR-T Programs ADEPT-2 Study Social Anxiety Disorder AI in Healthcare Major Depressive Disorder Pemvidutide Breast Cancer Immunotherapy Companion Diagnostics RAP-219 Program Cancer Treatment
Want to see what podcasts are saying about this topic? Search across 140K+ podcasts. Explore Radar
FDA briefing documents that raised scientific and regulatory doubts about the drug's statistical methods prompted the suit with a September 28, 2026 deadline for investors to seek lead‑plaintiff status.
